<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECT: A novel postsynaptic <z:chebi fb="68" ids="48706">antagonist</z:chebi> of <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> (<z:chebi fb="0" ids="31882">NMDA</z:chebi>) receptors, CP-101,606-27 may attenuate the effects of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In current experiments, the authors investigated its neuroprotective effect alone and in combination with recombinant tissue plasminogen activator (rt-PA) in thromboembolic focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Forty-eight male Wistar rats underwent embolization of the right middle cerebral artery to produce focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>After random division into six groups (eight rats in each group), animals received: vehicle; low-dose (LD) CP-101, 606-27, 14.4 mg/kg; high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) CP- 101,606-27, 28.8 mg/kg; rt-PA, 10 mg/kg; low-dose combination (LDC) CP- 101,606-27, 14.4 mg/kg plus rt-PA, 10 mg/kg; or high-dose combination (HDC) CP- 101,606-27, 28.8 mg/kg plus rt-PA, 10 mg/kg) 2 hours after induction of embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Animals were killed 48 hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">Brain infarction</z:e> volume, neurobehavioral outcome, poststroke <z:hpo ids='HP_0001250'>seizure</z:hpo> activity, poststroke mortality, and <z:hpo ids='HP_0002170'>intracranial hemorrhage</z:hpo> incidence were observed and evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with vehicle-treated animals (39.4 +/- 8.6%) 2 hours posttreatment with CP-101,606-27 or rt-PA or in combination a significant reduction in the percentage of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume was seen (LD CP-101,606-27: 20.8 +/- 14.3%, p &lt; 0.05; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> CP-101,606-27: 10.9 +/- 3.2%, p &lt; 0.001; rt-PA: 21.1 +/- 7.3%, p &lt; 0.05; LDC, 18.6 +/- 11.5%, p &lt; 0.05; and HDC: 15.2 +/- 10.1%, p &lt; 0.05; compared with control: 39.4 +/- 8.6%) </plain></SENT>
<SENT sid="7" pm="."><plain>Combination of CP-101,606-27 with rt-PA did not show a significantly enhanced neuroprotective effect </plain></SENT>
<SENT sid="8" pm="."><plain>Except for the control and LDC treatment groups, neurobehavioral outcome was significantly improved 24 hours after embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> in animals in <z:hpo ids='HP_0000001'>all</z:hpo> other active therapeutic groups receiving CP-101,606-27 or rt-PA or in combination </plain></SENT>
<SENT sid="9" pm="."><plain>The authors also observed that treatment with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> CP-101,606-27 decreased poststroke <z:hpo ids='HP_0001250'>seizure</z:hpo> activity </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The data in this study suggested that postischemia treatment with CP-101,606-27 is neuroprotective in the current <z:hpo ids='HP_0001297'>stroke</z:hpo> model; however, the authors also note that although rt-PA may offer modest protection when used alone, combination with CP-101,606-27 did not appear to enhance its effects </plain></SENT>
</text></document>